20190415_MBZ_COVR_04

Olga Zolotarskaya and Kennard Brunson work in the lab of WynnVision at the Virginia Bio+Tech Park in downtown Richmond, where various businesses and organizations employ about 2,400 people.

WynnVision, a biomedical nanofilms company based in the Virginia Bio+Tech Center in downtown Richmond, has received a $1.5 million grant for research to help prevent infections associated with medical devices.

The grant from the National Heart, Lung, and Blood Institute is part of the National Institutes of Health’s Small Business Innovation Research FastTrack program designed to encourage small businesses to engage in research and development.

This funding follows a $225,000 award to the company in August 2018 to develop a new approach to reduce the incidence of ventilator-associated pneumonia and ventilator-related infections. The approach, led by WynnVision Senior Chemist Olga Zolotarskaya, does not use antibiotics or antimicrobials that can lead to “super-bugs.”

The new funding will be used for research on preventing infections due to endotracheal tubes.

“WynnVision was able to achieve milestones set in our Phase I grant, and the team is looking forward to continuing work in eliminating infections with comfort and safety for patients,” said Dr. Kenneth Wynne, founder and CEO of WynnVision.

Commenting is limited to Times-Dispatch subscribers. To sign up, click here.
If you’re already a subscriber and need to activate your access or log in, click here.

Load comments

You must be a full digital subscriber to read this article You must be a digital subscriber to view this article.